Results 11 to 20 of about 32,586 (241)

Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol

BMC Pharmacology and Toxicology, 2023
Plain Language Summary New Fondaparinux Protocol to Reduce the Risk of Blood Thickening and Blood Clots Formation in Adults with Kidney Disease and Heparin-induced Thrombocytopenia (drop in platelets after the use of heparin): A Test Study.
Dania Ghaziri, Hassan Dehaini, Mayyas Msheik, Marwan Bahmad, Maya Zorkot, George Abi Saad   +5 more
doaj   +2 more sources

Retrospective Analysis of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Women With Recurrent Spontaneous Abortion

Frontiers in Endocrinology, 2021
BackgroundTo compare the clinical efficacy of fondaparinux and LMWH and provide clinical evidence for the effectiveness of fondaparinux in the treatment of recurrent spontaneous abortion caused by PTS.MethodsA retrospective analysis was conducted for 120
Long Zhao, Shuqin Bi, Jinhua Fu, Lijuan Qi, Lin Li, Yinghui Fu   +5 more
doaj   +2 more sources

Fondaparinux Pre-, Peri-, and/or Postpartum for the Prophylaxis/Treatment of Venous Thromboembolism (FondaPPP)

Clinical and Applied Thrombosis/Hemostasis, 2021
We analyzed data for women who received fondaparinux for ≥7 days during pregnancy. The study retrospectively included women who received fondaparinux pre-, peri- and/or postpartum for ≥7 days for prophylaxis/venous thromboembolism (VTE) treatment at ...
Carl-Erik Dempfle MD, Jürgen Koscielny MD, Edelgard Lindhoff-Last MD, Birgit Linnemann MD, Irene Bux-Gewehr MD, Günther Kappert MD, Ute Scholz MD, Stefan Kropff MD, Sonja Eberle PhD, Peter Bramlage MD, Andreas Heinken PhD   +10 more
doaj   +2 more sources

Fondaparinux-associated Thrombocytopenia

Pakistan Journal of Medical Sciences, 2021
Heparin-induced thrombocytopenia (HIT) is an immune-mediated condition causing thrombocytopenia and paradoxical thrombosis after exposure to heparin or low-molecular-weight heparin. It has been rarely reported by Fondaparinux, an artificial pentasaccharide similar to heparin. This manuscript presents a case of HIT associated with fondaparinux use.
Malik, Jahanzeb, Javed, Nismat, Kamin, Matiullah   +2 more
openaire   +4 more sources

Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)

Frontiers in Pharmacology
Background: Thromboembolic disease is associated with a high rate of disability or death and gravely jeopardizes people’s health and places considerable financial pressure on society.
Qinan Yin, Qinan Yin, Lizhu Han, Lizhu Han, Yin Wang, Fengjiao Kang, Fengqun Cai, Liuyun Wu, Xingyue Zheng, Lian Li, Li e Dong, Limei Dong, Shuhong Liang, Min Chen, Min Chen, Yong Yang, Yong Yang, Yuan Bian, Yuan Bian   +18 more
doaj   +2 more sources

Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban

Platelets, 2020
HIT, a prothrombotic disorder caused by heparin-dependent antibodies, is often treated with fondaparinux, usually with good outcomes. A 70-year-old female developed severe HIT (platelet count, 25 × 109/L) post-glioblastoma resection during heparin ...
Farheen Manji, Theodore E. Warkentin, Jo-Ann I. Sheppard, Adrienne Lee   +3 more
doaj   +2 more sources

Recurrent thrombosis rescued by fondaparinux in high‐risk patients: A case series

Research and Practice in Thrombosis and Haemostasis, 2022
Background Recurrent thrombosis treatment options are limited when anticoagulation with dose escalation of low molecular weight heparin or unfractionated heparin fail. Fondaparinux is a pure, synthetic pentasaccharide that consists of heparin's essential
Mégane Tanguay, Chantal Séguin
doaj   +2 more sources

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa

Clinical and Applied Thrombosis/Hemostasis, 2020
Andexanet alfa is a recombinant factor Xa decoy protein, designed to reverse bleeding associated with oral anti-Xa agents. Andexanet alfa is also reported to neutralize the effects of heparin-related drugs.
Fakiha Siddiqui BDS, Alfonso Tafur MD, Emily Bontekoe BS, Omer Iqbal MD, Walter Jeske PhD, Siddharth Mehrotra, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Jawed Fareed PhD   +8 more
doaj   +2 more sources

Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study

Frontiers in Medicine, 2020
Importance: The use of anticoagulant therapy with heparins decreased mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19). Even if enoxaparin and fondaparinux have the same clinical indication for venous thromboembolism (VTE)
Vincenzo Russo, Giuseppe Cardillo, Giuseppe Vito Viggiano, Sara Mangiacapra, Antonella Cavalli, Andrea Fontanella, Federica Agrusta, Annamaria Bellizzi, Maria Amitrano, Mariateresa Iannuzzo, Clara Sacco, Corrado Lodigiani, Giampiero Castaldo, Pierpaolo Di Micco   +13 more
doaj   +2 more sources

Comparison of efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism in lower extremities after total hip arthroplasty and total knee arthroplasty: a retrospective study of 592 patients

BMC Surgery
Objectives To compare the efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism (DVT) in lower extremities after total hip arthroplasty (THA) and total knee arthroplasty (TKA).
Xiang Gao, Xiaowei Jin, Rui Huang, Zhenxing Li, Hanle Zhang, Pei Fan   +5 more
doaj   +2 more sources